: The shared signature of BO as determined through analysis of the BO signature in 3 gene expression microarray studies. All studies were examined at the same cut off (p<0.001, Mann-Whitney non-parametric testing, fold change>1.5) using normal squamous tissue within each study as control. The combined signature was then derived by Venn diagram between the resulting gene lists. Table S4 : Gene expression microarray studies of normal and cancer tissues utilized.
Supplementary methods:

Gene expression microarray analyses and informatics
Conversion and hybridization of cRNA was performed by Almac Group Sciences (Craigavon, UK) and cRNA samples were hybridized to Affymetrix HGU133A plus 2.0 gene chips. Informatic and statistical analysis was performed using Genespring™ (Agilent). Data acquisition and .cel file generation was performed by GCOS followed by normalization by robust multichip average (RMA) in Genespring™ software.
Original .cel .chp files for normal gastro-intestinal tissues are available at the gene expression omnibus (GSE40220). Gene expression microarray study data of BE and
EAC patient biopsies by Kimchi et al (GSE1420),[1] Ostrowski et al (GSE36223),[2]
Silvers et al (GSE37203) [3] and Wang et al (GSE26886) [4] were acquired from the gene expression omnibus and utilized to examine the intestinal signature of BE and Table) .
Statistical re-analysis of these datasets was performed using HGU133A annotation data mask to provide a common platform of gene/probe numbers and a common statistical approach (Non-parametric Mann-Whitney testing at p<0.001, between controls and disease tissue all with fold change cut-off at FC=1.5) to interpretation between all platforms. Gene networking model interpretation of the data was performed using Ingenuity Pathway Analysis (IPA) (www.ingenuity.com, Redwood City, CA, USA). 
